Approved for use through 04/30/2009, 0MB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A "PRIOR" PATENT	Al 7391C1
In re Application of: James F. Allsup	
Application No.: 10/785,473	
Filed: February 24, 2004	
For: LONG TERM DISABILITY OVERPAYMENT RECOVERY SERVICE WITH INTERACTIVE CLIENT COMPONENT	
The owner*, <u>Alsup, Inc.</u> of 100 percent Interest in the Instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patient granted on the instant application which would extend beyond the expiration date of the full statutory term prior patient No. <u>7.280,548</u> as the term of said prior patient is defined to 35 U.S.C. 134 and 173, and as the term of said prior patient is defined to 35 U.S.C. 134 or 13	
In making the above disclaimer, the owner does not disclaim the terminal part of the item of any patent granted on the instant application that would extend to the expiration date of the fall statutory term as defined in SQ U.S. C. 154 and 73 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later expires for failure to pay a maintenance fee; is held unenfloreable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a recarraintation certificate;	
is reissued; or Is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Observation of the Control of the Co	
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on the made here of my own knowledge are true and that all statements made and belief are believed to be true; and further that these statements were made with the knowledge that wilfulf less statements ind fine the properties of the United States Code and that such wilfulf false statements have proporatize the validity of the application or any patient issued thereon.	
2. The undersigned is an attorney or agent of record. Reg. No. 35,989	
That W. Tuese	April 10, 2009
Signature	Date
Ned W. Randle Typed or printed name	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	(314) 238-2400
	Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information in required by 17 CPF 1.32. The information is required by other or retein, a benefit by the public which is 18 fix good by the LSFTO or processing an opposition. Confidentiality is governed by 28 LS of 122 and 37 CFF 11 and 114. The Incodession is estimated to lake 12 minuted to complete, including gathering, proparing, and submitting the completed application from to the USPTO. Time will say depending upon the individual case. Any comments on the amount of time pour require to complete this form anadott suggestions for refunding this burden, should be sent to the Criter information Officer. U.S. Patient and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Maxandria, VA 2231-31460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patients, P.O. Box 1450, Maxandria, VA 2231-31460.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form elated to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 L.S.C. 552) and the Privacy Act (6 L.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to oposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, bo whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 5624m1.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, on hisher designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued natent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.